Becoming an investigative journalist is a rewarding journey. It involves uncovering hidden truths and holding power to account. This guide will help you start your path in investigative journalism, ...

2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Teva reported growth for the second year in a row. Despite exceeding Wall Street targets, the company's guidance came up short. Teva reported earnings before trading began on Wednesday. The ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Teva Pharmaceutical reports fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion. Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in ...

The FDA has accepted Alvotech (NASDAQ:ALVO) and Teva's (NYSE:TEVA) Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria.

Alisha Goel represents plaintiffs and defendants in complex and high-stakes litigation. Her experience spans all stages of litigation, including pleadings, discovery, motions practice, and trial.